

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2024

DAY ONE BIOPHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-40431
(Commission File Number)

83-2415215
(IRS Employer
Identification No.)

2000 Sierra Point Parkway, Suite 501
Brisbane, California
(Address of Principal Executive Offices)

94005
(Zip Code)

Registrant's Telephone Number, Including Area Code: (650) 484-0899

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	DAWN	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On February 26, 2024, Day One Biopharmaceuticals, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this report.

Item 7.01 Regulation FD Disclosure.

On February 26, 2024, Day One Biopharmaceuticals, Inc. updated its corporate presentation. A copy of the updated presentation is attached as Exhibit 99.2 to this report.

The information in this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Current Report on Form 8-K and in the accompanying Exhibit 99.1 and Exhibit 99.2 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press release issued by Day One Biopharmaceuticals, Inc. regarding its financial results for the quarter and year ended December 31, 2023, dated February 26, 2024.
99.2	Corporate Presentation.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DAY ONE BIOPHARMACEUTICALS, INC.

Date: February 26, 2024

By: /s/ Charles N. York II, M.B.A.
Charles N. York II, M.B.A.
Chief Operating Officer and Chief Financial Officer



Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains

set for April 30, 2024

Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine

Ended 2023 with \$366.3 million in cash, cash equivalents and short-term investments providing runway into 2026

BRISBANE, Calif., Feb. 26, 2024 – Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its fourth quarter and full year 2023 financial results and highlighted recent corporate achievements.

“We have a monumental year ahead of us at Day One with the upcoming PDUFA date for tovorafenib,” said Jeremy Bender, Ph.D., chief executive officer of Day One. “Our team is trained and ready to deliver our first expected commercial medicine to children in need of new treatment options. We also continue to advance our Phase 3 front-line trial with tovorafenib and are actively exploring other potential additions to our pipeline for children and adults living with cancer.”

Program Highlights

- In October 2023, Day One announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for Priority Review of tovorafenib. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024. The Company anticipates being eligible for a Priority Review Voucher upon potential approval of tovorafenib.
 - In November 2023, *Nature Medicine* published the registrational Phase 2 FIREFLY-1 trial results investigating tovorafenib in patients with BRAF-altered, relapsed or progressive pediatric low-grade glioma (pLGG).
 - In the fourth quarter of 2023, Day One continued its commercial preparedness for the approval and launch of tovorafenib with the hiring of 18 sales representatives in the U.S.
 - The pivotal Phase 3 FIREFLY-2/LOGGIC clinical trial evaluating tovorafenib as a front-line therapy in patients aged 6 months to 25 years with pLGG continues to enroll in the United States, Canada, Europe, Australia and Asia, with more than 80 sites activated.
-

- Patient enrollment continues in the Phase 1b/2 substudy (102b) of the FIRELIGHT-1 trial evaluating the combination of tovorafenib with the Company's investigational MEK inhibitor, pimasertib.

Corporate Highlights and Upcoming Milestones

- Elly Barry, MD, has been promoted to Chief Medical Officer where she will lead the execution and expansion of Day One's clinical development programs. Most recently, Dr. Barry was Head of Clinical Development at Day One where she played an integral role in the execution of the Company's clinical programs. Prior to joining the Company in 2021, Dr. Barry was Global Clinical Lead for Pediatric Oncology at Pfizer, as well as Head of Pfizer's Pediatric Oncology Leadership Team where she oversaw multiple oncology clinical programs. She has replaced Raphaël Rousseau, MD, PhD, who has transitioned into a strategic advisory consulting role into the second quarter of 2024.
- Day One welcomed seasoned biotechnology veterans Habib Dable and Dr. William Grossman to its Board of Directors. Both individuals bring deep expertise and leadership in oncology to the Company's Board.
- The recommended Phase 2 dose and schedule in the FIRELIGHT-1 clinical trial is expected in 2H 2024.

Fourth Quarter and Full Year 2023 Financial Highlights

- **Cash Position:** Cash, cash equivalents and short-term investments totaled \$366.3 million on December 31, 2023. Based on Day One's current operating plan, management believes it has sufficient capital resources to fund anticipated operations into 2026.
- **R&D Expenses:** Research and development expenses were \$37.3 million and \$130.5 million for the fourth quarter and full year ended December 31, 2023, respectively, as compared to \$26.0 million and \$85.6 million for the same periods in 2022. The increase was primarily due to additional employee compensation costs, a milestone payment, as well as clinical trial and manufacturing activities related to Day One's lead product candidate, tovorafenib.
- **G&A Expenses:** General and administrative expenses were \$22.2 million and \$75.5 million for the fourth quarter and full year ended December 31, 2023, respectively, as compared to \$16.7 million and \$61.3 million for the same periods in 2022. The increase was primarily due to additional employee compensation costs, an ongoing commercial buildout, and professional service expenses to support company growth.
- **Net Loss:** Net loss totaled \$54.5 million for the fourth quarter of 2023 with non-cash stock compensation expense of \$10.8 million, compared to \$40.1 million for the fourth quarter of 2022 with non-cash stock compensation expense of \$6.8 million. Net loss was \$188.9 million for the year ended December 31, 2023, with non-cash stock compensation expense of \$39.3 million, compared to \$142.2 million for the year ended December 31, 2022, with non-cash stock compensation expense of \$27.2 million.

Upcoming Events

- **44th Annual TD Cowen Health Care Conference**

- o Management will participate in a fireside chat on Tuesday, March 5 at 9:50 a.m. ET. A live and archived audio webcast of the discussion will be available by visiting the Events & Presentations section of the Company's website.

About Tovorafenib

Tovorafenib is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is being investigated in primary brain tumors or brain metastases of solid tumors. Tovorafenib is currently under evaluation in two pivotal clinical trials for pLGG. Tovorafenib is also being evaluated as a combination therapy for adolescent and adult patient populations with recurrent or progressive solid tumors with MAPK pathway aberrations (FIRELIGHT-1).

Tovorafenib has been granted Breakthrough Therapy and Rare Pediatric Disease designations by the FDA for the treatment of patients with pLGG harboring an activating RAF alteration. Tovorafenib has also received Orphan Drug designation from the FDA for the treatment of malignant glioma, and from the European Commission for the treatment of glioma.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. We put kids first and are developing targeted therapies that deliver to their needs. Day One was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. The Company's name was inspired by "The Day One Talk" that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. Day One aims to re-envision cancer drug development and redefine what's possible for all people living with cancer—regardless of age—starting from Day One.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company's lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. The Company's pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). Day One is based in Brisbane, California. For more information, please visit www.dayonebio.com or find the Company on LinkedIn or X.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Day One's plans to develop cancer therapies, expectations from current clinical trials, the execution of the Phase 2 and Phase 3 clinical trials for tovorafenib as designed, any expectations about safety, efficacy, timing and ability to complete clinical trials, release data results, the ability of Day One to obtain regulatory approvals for and to commercialize tovorafenib and other candidates in development, and the ability of tovorafenib to treat pLGG or related indications.

Statements including words such as "believe," "plan," "continue," "expect," "will," "develop," "signal," "potential," or "ongoing" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements.

Forward-looking statements are subject to risks and uncertainties that may cause Day One's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties in this press release and other risks set forth in our filings with the Securities and Exchange Commission, including Day One's ability to develop, obtain regulatory approval for or commercialize any product candidate, Day One's ability to protect intellectual property, the potential impact of global business or macroeconomic conditions, including as a result of inflation, changing interest rates, potential instability in the global banking system, uncertainty with respect to the federal debt ceiling and budget and potential government shutdowns related thereto and global regional conflicts and the sufficiency of Day One's cash, cash equivalents and investments to fund its operations. These forward-looking statements speak only as of the date hereof and Day One specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.

Day One Biopharmaceuticals, Inc.
Consolidated Statements of Operations
(unaudited)
(in thousands, except shares)

	Year Ended December 31,		
	2023	2022	2021
Operating expenses:			
Research and development	\$ 130,521	\$ 85,618	\$ 43,584
General and administrative	75,543	61,291	29,159
Total operating expenses	206,064	146,909	72,743
Loss from operations	(206,064)	(146,909)	(72,743)
Investment income, net	17,187	4,746	4
Other expense, net	(40)	(18)	(15)
Net loss	(188,917)	(142,181)	(72,754)
Net loss attributable to redeemable convertible noncontrolling interest	—	—	(2,109)
Exchange of redeemable noncontrolling interest shares – deemed dividend	—	—	(99,994)
Net loss attributable to common stockholders/members	\$ (188,917)	\$ (142,181)	\$ (170,639)
Net loss per share, basic and diluted	\$ (2.37)	\$ (2.17)	\$ (4.62)
Weighted-average number of common shares used in computing net loss per share, basic and diluted	79,773,004	65,466,773	36,960,569

Day One Biopharmaceuticals, Inc.
Selected Consolidated Balance Sheet Data
(unaudited)
(in thousands)

	December 31, 2023	December 31, 2022
Cash, cash equivalents and short-term investments	\$ 366,347	\$ 342,269
Total assets	376,048	349,062
Total liabilities	29,508	17,023
Accumulated deficit	(458,585)	(269,668)
Total stockholders' equity	346,540	332,039

DAY ONE MEDIA
Laura Cooper, Head of Communications
media@dayonebio.com

DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com


#####



Day One Biopharmaceuticals

Targeted Therapies for People of All Ages

February 2024



Disclaimer

This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "intend," "potential," "would," "continue," "ongoing" or the negative of these terms or other comparable terminology. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our future financial performance, including the sufficiency of our cash, cash equivalents and short-term investments to fund our operations, business plans and objectives, timing and success of our planned nonclinical and clinical development activities, the results of any of our strategic collaborations, including the potential achievement of milestones and provision of royalty payments thereunder, timing and results of nonclinical studies and clinical trials, efficacy and safety profiles of our product candidates, execution of the Phase 2 and Phase 3 clinical trials for tovorafenib and the Phase 1b/2 clinical trial for tovorafenib and pimasertib as designed, any expectations about safety, efficacy, timing and ability to complete clinical trials and to obtain regulatory approvals for tovorafenib and other candidates in development, the ability of tovorafenib to treat pediatric low-grade glioma (pLGG) or related indications, the potential therapeutic benefits and economic value of our product candidates, potential growth opportunities, competitive position, industry environment and potential market opportunities, our ability to protect intellectual property and the impact of global business or macroeconomic conditions, including as a result of inflation, changing interest rates, potential instability in the global banking system, uncertainty with respect to the federal debt ceiling and budget and potential government shutdowns related thereto and global regional conflicts, on our business and operations.

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These factors, together with those that are described under the heading "Risk Factors" contained in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") and other documents we file from time to time with the SEC, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements.

In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.



Cancer Therapies for People of All Ages



Our Approach

- Develop medicines for genomically-defined cancers
- Establish first-in-class position through rapid registration pathways
- Expand to adolescent and adult populations in parallel and pursue those opportunities with the same commitment we do for children



Our Pipeline

Product Candidate	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Recent & Anticipated Milestones
Tovorafenib (DAY101) Type II RAF Inhibitor <ul style="list-style-type: none"> FDA Breakthrough Therapy Designation for relapsed pLGG FDA Rare Pediatric Disease Designation (PRV Eligible) for pLGG FDA Orphan Drug Designation for malignant glioma EC Orphan Designation for glioma 	BRAF-altered Relapsed pLGG	FIREFLY-1* (pivotal)				FDA acceptance of NDA: October 2023 PDUFA target action date: April 30, 2024 Data published in <i>Nature Medicine</i> : November 2023
	Frontline RAF-altered pLGG	FIREFLY-2 (pivotal)				First patient dosed: March 2023
Pimasertib MEK 1/2 Inhibitor	MAPK-altered solid tumors† (Combo w/ tovorafenib)	FIREFLIGHT-1††				Recommended Phase 2 dose & schedule expected: 2H 2024
VRK1 Program§ VRK1 Inhibitor	Pediatric and adult cancers					In-licensed: August 2023



4 | * FIREFLY-1 Arm 1 expected to support registration. † Pimasertib Phase 1 dose escalation and expansion trial previously completed. †† Includes patients ≥12 years of age. § Research collaboration and license agreement with Sprint Bioscience AB for exclusive worldwide rights to a research-stage program targeting VRK1. pLGG, pediatric low-grade glioma. Tovorafenib and Pimasertib are investigational products. Safety and efficacy have not been established by any health authority.



Tovorafenib (DAY101)

Type II RAF Inhibitor

Kids like Sawyer spend most of their childhood as patients rather than children

3 (1-9)

Median (range) number of lines
of prior systemic therapy ¹

51%

Percentage of patients who had
greater than or equal to 3 lines
of prior systemic therapy ¹



6 Sawyer, lives with pLGG. ¹ Figures come from FIREFLY-1 baseline patient characteristics with a June 5, 2023 data cutoff. Total patients enrolled in arm 1 of the FIREFLY-1 trial was 77.

Pediatric Low-Grade Glioma (pLGG): The Most Common Type Of Brain Tumor In Children

pLGGs are chronic and relentless, with patients suffering profound tumor and treatment-associated morbidity that can impact their life trajectory over the long term⁹

A Serious and Life-Threatening Disease

- An estimated 26,000 children/young adults are living with *BRAF*-altered pLGGs in the U.S. today^{1,2}
- For the majority of patients in the relapsed setting, there is no standard of care and no approved therapies
- Surgery plays a significant role in treatment, but vast majority of patients require systemic therapy^{3,4}
- ~70% of pLGGs have *BRAF* alterations, which means ~55% of pLGGs are *BRAF* fusions and ~15% are *BRAF* V600E mutations⁵⁻⁸

Disease Symptoms¹⁰

Cerebral gliomas:


Seizures, muscle weakness, behavioral changes

Hypothalamic gliomas:

Endocrine dysfunction and visual deficits

Optic pathway gliomas:

Decreased vision (acuity and/or fields), bulging or misalignment of eyes



Cerebellar gliomas:

Impaired balance, coordination or depth perception

Brain stem gliomas:

Difficulty swallowing or with speech, abnormal breathing



¹ CBTRUS, Qaddoumi et al 2009, Schreck et al 2019, ClearView Analysis; ² SEER US complete prevalence counts of patients aged under 25 with Brain and Other Nervous Systems tumors as of January 1, 2017. Estimated prevalence are Day One calculations based on publicly available data. ³ Ostrum QT et al., *Neuro Oncol.* 2015; 16(Suppl 10):x1-x36; ⁴ De Blank P. et al., *Curr Opin Pediatr.* 2019 Feb; 31(1):21-27. ⁵ Chen Y-H, Gutmann DH. *Oncogene.* 2014;33(16):2019-2026. ⁶ Packer RJ et al. *Neuro Oncol.* 2017;19(6):750-761. ⁷ Ryall S, et al. *Cancer Cell.* 2020;37(4):569-583. ⁸ Ryall S, Tabori U, Hawkins C Acta Neuropathol Commun. 2020;8(1):30. ⁹ Traunwieser T et al., *Neurooncol Adv.* 2020; 2:vdaa094. ¹⁰ Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. *J Child Neurol.* 2009;24(11):1397-1408. doi:10.1177/0883073809342005.

Conventional Treatments Can Be Disruptive To Childhood and Can Have Significant Long-Term Consequences

Surgery

- Significant recovery times
- Risks of complications
- Resection may be limited by location of tumor
- Potential for functional deficits based on location of tumor and extent of resection

Chemotherapy

- Requirement for indwelling catheter and weekly infusions
- Risk of neutropenia, hypersensitivity reactions, nausea and vomiting and peripheral neuropathy


Radiation

- Risk of secondary malignancy
- Risk of malignant transformation
- Risk of vascular proliferation and stroke
- Neurocognitive impact, depending on location of tumor and radiation field

Clear need for an effective therapy for the majority of pLGG relapsed or progressive patients that is minimally disruptive to their lives.



Tovorafenib (DAY101) Inhibits Both BRAF Fusions And BRAF V600 Mutations



Tovorafenib (DAY101) is an investigational, oral, selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF kinase

- Activity in tumors driven by both RAF fusions and BRAF V600E mutations
- Tablet and pediatric-friendly liquid suspension
- Once weekly dosing

Currently approved type I BRAF inhibitors are indicated for use in patients with tumors bearing BRAF V600E mutations

- Type I BRAF inhibitors cause paradoxical MAPK activation in the setting of wild-type RAF, increasing the risk of tumor growth in BRAF fusion-driven

Pivotal Phase 2 Trial Of Monotherapy Tovorafenib (DAY101) In Relapsed Or Progressive pLGG (FIREFLY-1) – Fully Enrolled & Data Accepted by FDA




Trial Design

- Three arm, open-label, global registrational phase 2 trial
- **Pivotal Arm 1 (recurrent/progressive pLGG, n=77):** harboring a KIAA1549-BRAF fusion or BRAF V600E mutation
- Arm 2 (expanded access recurrent/progressive LGG, n=60): harboring an activating RAF alteration
- Arm 3 (extracranial solid tumors): harboring an activating RAF fusion

Endpoints (Pivotal Arm 1)

- **Primary endpoint:** ORR based on RANO-HGG¹, assessed by blinded independent central review
- **Secondary endpoints:** ORR by RAPNO-LGG² assessed by blinded independent central review; PFS, DoR; TTR, CBR; safety
- **Exploratory analyses:** ORR and CBR by RANO-LGG³ assessed by blinded independent central review






Data from Pivotal Phase 2 FIREFLY-1 Trial

June 5, 2023 data cutoff


FIREFLY-1 Baseline Patient Characteristics



Characteristic	Arm 1 (n=77)
Median age, years (range)	8 (2-21)
Sex, n (%)	
Male	40 (52)
Female	37 (48)
Race, n (%)	
White	41 (53)
Asian	5 (6)
Black	2 (3)
Multiple	3 (4)
Other	6 (8)
Not specified	20 (26)
Number of lines of prior systemic therapy	
Median (range)	3 (1-9)
1, n (%)	17 (22)
2, n (%)	21 (27)
≥3, n (%)	39 (51)
Prior MAPK pathway targeted therapy, n (%)	
Prior MEK inhibitor	43 (56)
Prior BRAF inhibitor	8* (10)
Prior BRAF and MEK inhibitors†	5 (7)
Any MAPK inhibitor	46 (60)




BRAF alteration (n=77)



12 June 5, 2023 data cutoff. †Includes 6 patients with BRAF duplication and 2 with BRAF rearrangement per fluorescence in situ hybridization or in situ hybridization. ‡Includes tumors that were extending into multiple regions of the brain, leptomeningeal disease, and/or spinal disease. †The 5 patients that had previously received both a MEK inhibitor and also a BRAF inhibitor are recorded in both the "Prior MEK inhibitor" and "Prior BRAF inhibitor" groups. MAPK, mitogen-activated protein kinase.


Tumor Response To Tovorafenib (DAY101) Using RAPNO-LGG, RANO-LGG and RANO-HGG




Response (IRC)	RAPNO-LGG n=76	RANO-LGG N=76	RANO-HGG N=69
ORR,* n (%)	39 (51)	40 (53)	46 (67)
95% CI	40-63	41-64	54-78
CBR,* n (%)			
SD of any length of time	62 (82)	63 (83)	64 (93)
SD ≥12 months	43 (57)	46 (61)	54 (78)
BOR,* n (%)			
CR	0	0	12 (17)
PR	28 (37)	20 (26)	34 (49)
MR	11 (14)	20 (26)	n/a
SD	23 (30)	23 (30)	18 (26)
SD <12 months	19 (25)	17 (22)	10 (14)
SD ≥12 months	4 (5)	6 (8)	8 (12)
PD	13 (17)	11 (14)	4 (6)
NE	1 (1)	2 (3)	1 (1)
Median DOR, months	13.8	14.4	16.6
95% CI	11.3-NR	11.0-NR	11.6-NR
Median TTR, months	5.3	5.5	3.0
Range	1.6-11.2	1.6-11.3	2.6-16.6



Duration Of Tovorafenib (DAY101) Therapy For All Patients With RAPNO-LGG Evaluable Lesions




Tumor Kinetics In Patients With Best Response Of Progressive Disease According To RAPNO-LGG



The majority of patients who had radiographic progression by RAPNO-LGG at their initial disease assessment had subsequent prolonged reductions in the size of their tumor with continued treatment.

Tumor Response To Tovorafenib (DAY101) According To RAPNO-LGG In Subgroups Defined By Baseline Characteristics



Analysis of response data across various subgroups shows no significant differences in response rate by RAPNO-LGG.



Tumor Response To Tovorafenib (DAY101) Across Three Assessment Criteria Were Consistent Across BRAF Fusion And Mutation Patients, and Patients With Prior MAPK Treatment



Response (IRC)	RAPNO-LGG ²		RANO-LGG ^{3,4}		RANO-HGG ¹	
	n		n		n	
ORR,* n (%)	76	39 (51)	76	40 (53)	69	46 (67)
BRAF fusion	64	33 (52)	64	33 (52)	59	41 (69)
BRAF mutation	12	6 (50)	12	7 (58)	10	5 (50)
Prior MAPKi	45	22 (49)	45	23 (51)	41	29 (71)
MAPKi-naive	31	17 (55)	31	17 (55)	28	17 (61)
CBR,* n (%) (SD of any length of time)	76	62 (82)	76	63 (83)	69	64 (93)
BRAF fusion	64	53 (83)	64	53 (83)	59	55 (93)
BRAF mutation	12	9 (75)	12	10 (83)	10	9 (90)
Prior MAPKi	45	38 (84)	45	38 (84)	41	37 (90)
MAPKi-naive	31	24 (77)	31	25 (81)	28	27 (96)
CBR,* n (%) (SD ≥12 months)	76	43 (57)	76	46 (61)	69	54 (78)
BRAF fusion	64	37 (58)	64	39 (61)	59	49 (83)
BRAF mutation	12	6 (50)	12	7 (58)	10	5 (50)
Prior MAPKi	45	25 (56)	45	26 (58)	41	33 (80)
MAPKi-naive	31	18 (58)	31	20 (65)	28	21 (75)
Median DOR, months (95% CI)**	39	13.8 (11.3-NR)	40	14.4 (11.0-NR)	46	16.6 (11.6-NR)
BRAF fusion	33	13.8 (11.3-NR)	33	16.3 (11.0-NR)	41	16.8 (11.6-NR)
BRAF mutation	6	NR (8.4-NR)	7	12.0 (8.4-NR)	5	15.1 (8.3-NR)
Prior MAPKi	22	13.8 (11.3-NR)	23	12.0 (8.5-NR)	29	15.1 (9.0-16.8)
MAPKi-naive	17	NR (8.4-NR)	17	16.3 (8.4-NR)	17	NR (11.6-NR)

17 June 5, 2023 data cutoff. ¹ Fangusaro J, et al. *Lancet Oncol.* 2020;21(6):e305–316. ² Fangusaro J, et al. *Lancet Oncol.* 2020;21(6):e305–316. ³ van den Bent MJ, et al. *Lancet Oncol.* 2011;12(6):583-593. ⁴ Wen PY, et al. *J. Clin Oncol.* 2017;35(21):2439-2449. * ORR, CBR for RAPNO-LGG and RANO-LGG included MRs. ** the 95% CI were calculated using Kaplan-Meier method.




Tovorafenib (DAY101) Safety Data (n=137)



Preferred Term, n (%)	TEAEs		TRAEs	
	Any Grade	Grade ≥3	Any Grade	Grade ≥3
Any AE	137 (100)	86 (63)	134 (98)	58 (42)
Hair color changes	104 (76)	0	104 (76)	0
Anemia	81 (59)	15 (11)	67 (49)	14 (10)
Elevated CPK	80 (58)	16 (12)	77 (56)	16 (12)
Fatigue	76 (55)	6 (4)	60 (44)	6 (4)
Vomiting	68 (50)	6 (4)	28 (20)	3 (2)
Hypophosphatemia	64 (47)	0	48 (35)	0
Headache	61 (45)	2 (1)	29 (21)	0
Maculo-papular rash	60 (44)	11 (8)	56 (41)	11 (8)
Pyrexia	53 (39)	5 (4)	17 (12)	1 (1)
Dry skin	49 (36)	0	45 (33)	0
Elevated LDH	48 (35)	0	42 (31)	0
Increased AST	47 (34)	4 (3)	41 (30)	4 (3)
Constipation	45 (33)	0	31 (23)	0
Nausea	45 (33)	0	25 (18)	0
Upper RTI	43 (31)	2 (1)	2 (1)	0
Dermatitis acneiform	42 (31)	1 (1)	41 (30)	1 (1)
Epistaxis	42 (31)	1 (1)	27 (20)	0
Decreased appetite	39 (28)	5 (4)	28 (20)	4 (3)
Paronychia	36 (26)	2 (1)	32 (23)	2 (1)
Pruritus	35 (26)	1 (1)	32 (23)	1 (1)
COVID-19	34 (25)	0	0	0

- The most common reasons for discontinuation were tumor hemorrhage (3 patients) and decrease in growth velocity (2 patients)
- 33 patients (24%) had TRAEs leading to dose reduction; 50 patients (37%) had TRAEs leading to dose interruption
- Median duration of dose interruption was 2 weeks
- 9 patients (7%) had TRAEs leading to discontinuation

Estimated *BRAF*-Altered pLGG Patient Population In The U.S.



The estimated addressable pool of recurrent or progressive pLGG patients is ~2,000-3,000⁶ per year at steady state*



¹ Selt F, van Tilburg CM, Bison B, et al. Response to trametinib treatment in progressive pediatric low-grade glioma patients. *J Neurooncol.* 2020;149(3):499-510. doi:10.1007/s11060-020-03640-3. ² Ryall S, Tabori U, Hawkins C. Pediatric low-grade glioma in the era of molecular diagnostics. *Acta Neuropathol Commun.* 2020;8(1):30. doi:10.1186/s40478-020-00902-z. ³ SEER US complete prevalence counts of patients aged under 25 with Brain and Other Nervous Systems tumors as of January 1, 2017. ⁴ CBRUS, Qaddoumi et al 2009, Schreck et al 2019, ClearView Analysis. ⁵ US Census. Estimated annual incidence, estimated prevalence, and estimated recurrent/progressive total addressable patient population are Day One calculations based on publicly available data. ⁶ Source: Internal market research conducted by EpidStrategies, A Division of ToxStrategies, Inc. on behalf of Day One. * The estimated addressable pool of recurrent or progressive pLGG patients is based on progression free survival curves modeled from published literature.

Preparing for a Successful Launch*

Key Factors

- Communicate strong clinical profile for tovorafenib without significant disruption to childhood
- Enable patient access through establishing broad coverage and patient support programs
- Experienced, fully dedicated field sales force (18 U.S. Account Managers)
- Positive patient experience, drug profile consisting of once-weekly dosing (oral tablet or liquid formulation)

Priorities

Drive FIREFLY-1 Trial and Physician Awareness

Build momentum with pediatric oncologists at the ~200 U.S. Centers of Excellence

Enable unrestricted patient access



Key Takeaways From FIREFLY-1 Data And Next Steps

- Response rate is clinically meaningful from FIREFLY-1 for pediatric patients with recurrent or progressive LGG harboring *BRAF* fusions or *BRAF* V600E mutations (“*BRAF*-altered”)
 - **67% ORR by RANO-HGG**
 - **51% ORR by RAPNO-LGG**
 - **53% ORR by RANO-LGG**
- Deepening of responses observed in patients from December 2022 to June 2023 data cutoffs across all three assessment criteria
- Meaningful duration of response as of data cutoff (median times: 16.6 months with RANO-HGG, 13.8 months with RAPNO-LGG, and 14.4 months with RANO-LGG)*
- Responses were observed in patients with either *BRAF* fusion or *BRAF* V600E mutations
- Responses seen in a heavily-pretreated population where the majority (60%) of patients progressed on or after one or more prior MAPK inhibitors
- Safety and tolerability profile indicating monotherapy tovorafenib to be generally well-tolerated
- FDA Rare Pediatric Disease Designation for pLGG, eligible for Priority Review Voucher

Next Steps: Priority review granted with PDUFA target action date of April 30, 2024





FIREFLY-2 / LOGGIC

Pivotal Phase 3 Trial of Tovorafenib (DAY101)
in Frontline pLGG

FIREFLY-2/LOGGIC Pivotal Phase 3 Trial Of Tovorafenib (DAY101) In Frontline pLGG




Trial Design

- Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib (DAY101) vs SoC chemotherapy
- Eligibility: Patients aged 6 months to <25 years with LGG harboring a RAF alteration and requiring first-line systemic therapy
- Tovorafenib (DAY101) available as tablets and pediatric-friendly liquid suspension
- Patients who progress after stopping tovorafenib (DAY101) may be re-challenged
- Patients who progress in the SoC arm during or post-treatment may cross-over to receive tovorafenib

Endpoints

- **Primary endpoint: ORR based on RANO-LGG criteria, assessed by blinded independent central review¹**
 - **The ORR primary analysis is expected to occur ~12 months after the last patient randomized**
- Key secondary endpoints: PFS and DoR by RANO criteria, ORR by RAPNO criteria
- Other secondary endpoints: changes in neurological and visual function, safety, and tolerability
- Key exploratory objectives: QoL and health utilization measures



* COG or SIOpe-LGG regimen. Abbreviations: CHG, chiasmatic, hypothalamic glioma; DoR, duration of response; LGG, low-grade glioma; ORR, objective response rate; QoL, quality of life; QW, once weekly; SoC, standard of care.
¹ Primary endpoint of FIREFLY-2 will be ORR by RANO-LGG (2017) following full approval by FDA on March 16, 2023 of dabrafenib with trametinib in pediatric patients with low-grade glioma with a BRAF V600E mutation who require systemic therapy based on a study with the same primary endpoint.



FIRELIGHT-1



Phase 1b/2 Trials Evaluating Tovorafenib (DAY101)
as a Combination with Pimasertib

Pimasertib: Investigational Allosteric MEK1/2 Inhibitor With Demonstrated Activity In MAPK-Driven Solid Tumors

- Pimasertib is an investigational orally-bioavailable, selective, non-competitive MEK1/2 inhibitor in-licensed from Merck KGaA in February 2021
- Extensive non-clinical and clinical development work through Phase 2, including a solid tumor trial in Japan and combinations with other MOAs
- Main AEs typical for all in-class allosteric MEK inhibitors (GI, CPK elevation, skin rash, visual disturbances)
- Nearly three-fold higher CNS penetration than other MEKi inhibitors (trametinib or selumetinib)
- Pimasertib showed monotherapy clinical activity, including an improvement in median PFS versus dacarbazine in NRAS mutant melanoma
- Combination with tovorafenib (DAY101) and other targeted therapies may unlock the full value of pimasertib in advanced solid tumors



Vertical MAPK Pathway Inhibition With Tovorafenib (DAY101) And Pimasertib May Unlock Potential Synergy For Adult Solid Tumors



- A** Type II RAFi + MEKi is synergistic in BRAF fusion melanoma PDX model ex vivo (internal data)
- B** Sensitivity of KRAS Q61 mutant cells to pimasertib is enhanced when cells are treated with the type II BRAF inhibitor BGB-283 (Yuan et al., Mol Onc 2020)
- C** Tovorafenib (DAY101) + MEK inhibitor is synergistic in KRAS G12C and Q61 mutant tumor cells (Venetsanakos et al., 2021 AACR poster presentation)

Tovorafenib (DAY101) / Pimasertib Combination In Solid Tumors (FIRELIGHT-1)




Trial Design¹

- Combination dose escalation, global phase 1b/2 trial²
- Phase 1b, BOIN (adaptive), n = 10/cohort (approximately)
- Phase 2, Simon 2-stage, n = 25/cohort (approximately)
- Eligibility: Patients aged 12 years and older, dose escalation will be performed in advanced solid tumor patients with any MAPK alteration. Expansion cohorts will focus on indications with a potential path to accelerated approval

Endpoints

- Phase 1b: PK, PD and Safety, MTD/RP2D
- Phase 2: Efficacy (ORR, DOR)



Summary

Financial Summary: DAWN

Cash, cash equivalents and short-term investments as of December 31, 2023: \$366.3 million (no debt)

~87.4 million shares of common stock outstanding as of February 21, 2024

\$ Millions	Twelve Months Ended 12/31/23	Twelve Months Ended 12/31/22
R&D Expense	\$130.5	\$85.6
G&A Expense	\$75.5	\$61.3
Net Loss	\$188.9	\$142.2

Projected Cash Runway into 2026

FIREFLY-1: Pivotal Phase 2 clinical trial of tovorafenib (DAY101)

- NDA¹ in May 2023
- FDA acceptance of NDA and priority review granted in October 2023
- PDUFA target action date of April 30, 2024 (PRV eligible)
- Data published in *Nature Medicine* and oral presentations at SNO in November 2023

FIREFLY-2/LOGGIC: Pivotal Phase 3 clinical trial of tovorafenib (DAY101) in newly diagnosed pLGG

- First patient dosed in March 2023

29 | All financial and share information is unaudited. ¹NDA data set includes analysis of primary (ORR by RANO-HGG) and secondary (ORR by RAPNO, PFS) efficacy endpoints, safety, and exploratory analyses (including ORR by RANO-LGG). PRV, Priority Review Voucher.

2023 Key Accomplishments



FIREFLY-1: Relapsed or Progressive pLGG

- NDA initiated in May 2023
- Clinical data presented in oral presentation at ASCO in June 2023
- FDA acceptance of NDA and priority review granted in October 2023
- Data published in *Nature Medicine* and oral presentation at SNO in November 2023
- PDUFA target action date of April 30, 2024

FIREFLY-2: Frontline pLGG

- Dosed the first patient in March 2023

Business Development

- Research collaboration and license agreement for preclinical program targeting VRK1 in August 2023

Financials

- \$366.3 million in cash, cash equivalents and short-term investments as of December 31, 2023
- Cash runway into 2026

Priorities as we Expand into a Commercial-Stage Company

Launch Tovorafenib

- Secure the first FDA-approved targeted therapy for pLGG with *BRAF* fusions and point mutations that have relapsed or progressed
- Expand awareness amongst physicians and establish broad coverage to enable patient access
- Following approval, establish tovorafenib as the standard of care for relapsed or progressive pLGG

Advance Portfolio

- FIREFLY-2: Study tovorafenib as a frontline therapy for treatment-naive patients with pLGG
- FIRELIGHT-1: Evaluate tovorafenib in combination with pimasertib in adolescent and adult populations
- Advance early stage VRK1 program to clinical development


Expand Pipeline

- Grow Day One into a leading, biopharmaceutical company that is the partner of choice for oncology drug development
- Explore selective partnerships as a source of capital and risk sharing
- Further invest in business development activities to expand our multiple asset portfolio for both children and adults


Appendix



Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-HGG Evaluable Lesions




Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-LGG Evaluable Lesions





Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma

A 7-years-old female child with an optic pathway glioma, with very poor vision, entropion, folliculitis, eczema, mouth ulceration and xerosis




- PR (-58%) and improvement in vision reported at cycle 3
- AEs included grade 3 erythematous rash requiring dose interruption and dose reduction (400 mg QW to 300 mg QW in cycle 1), and grade 2 eczema and maculopapular rash
- Patient continues to receive weekly tovorafenib




Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma

An 8-years-old female child with a posterior fossa pilocytic astrocytoma, eczema, nausea and constipation




- PR (-69%) at cycle 3 with 500 mg QW tovorafenib, with a deepening of response (80% and 91% in cycles 6 and 9, respectively) over time
- AEs included grade 2 decrease in neutrophil count, pustular rash, and upper respiratory infection
- Patient continues to receive weekly tovorafenib




Case Study: Activity Of Tovorafenib (DAY101) In BRAF V600E Mutation Deep Midline Astrocytoma

A 9-year-old female child with deep midline BRAF V600E-mutant astrocytoma with precocious puberty



- PR (-74%) at cycle 3, with a deepening of response (-94%) at cycle 6
- AEs included grade 3 maculopapular rash and increased CPK, requiring drug interruption and dose reduction (500 mg QW to 400 mg QW in cycle 1)
- Tovorafenib dose was re-escalated back to 500 mg QW in cycle 4; patient continues on treatment






Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma

8-year-old boy with relapsed pilomyxoid astrocytoma of the optic pathway, with visual loss in right eye, visual field loss in left eye, fatigue, intermittent nausea/vomiting, intermittent headaches, anorexia, and temperature regulation disorder



- Initiated treatment with tovorafenib 400 mg/QW following 3 prior therapies, including binimetinib and trametinib, which were discontinued due to PD
- At cycle 3, **PR** (-88%) per RANO-HGG, and **MR** (-32% and -40%) per RAPNO-LGG and RANO-LGG, respectively
 - Sustained improvements in visual acuity reported; logMAR change 0.2 → 0
 - PD criteria met (-94% to -91%) with RANO-HGG at cycle 15; continued treatment as investigator deemed no radiographic progression with subsequent reduction in target lesion (-97%)
- AEs were G2 (drug eruption, elevated CPK) and G1 (hair color change, paronychia, growth retardation)



FIREFLY-2/LOGGIC: Pivotal Phase 3 Study Of Tovorafenib (DAY101) In Newly Diagnosed pLGG

- Collaboration between Day One and the LOGGIC consortium, internationally recognized experts in pLGG research
 - Coupled with the LOGGIC-CORE molecular diagnostic program
 - Worked jointly on the study design and discussions with the U.S. and EU regulatory authorities



Approximately 100 potential sites (~65 from the LOGGIC consortium)

